STOCK TITAN

[20-F/A] WPP PLC Amends Annual Report (Foreign Issuer)

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
20-F/A
Rhea-AI Filing Summary

BioNTech SE (BNTX) filed a Form 6-K to report a key regulatory milestone for its updated COVID-19 product line. The company and partner Pfizer received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommending marketing authorization of their LP.8.1-adapted, monovalent COMIRNATY LP.8.1 vaccine. The indication covers active immunization against COVID-19 in individuals 6 months of age and older.

The CHMP endorsement is the final step before formal approval by the European Commission, which typically follows within weeks. If ratified, the decision would allow BioNTech/Pfizer to launch the new strain-aligned booster across the EU ahead of the 2025-26 respiratory season, potentially expanding the addressable market to infants and broadening revenue streams.

No financial figures were disclosed in the filing; however, authorization would likely support near-term sales continuity as earlier-generation vaccine demand wanes. Management signatures and an exhibit index referencing the joint press release were included.

BioNTech SE (BNTX) ha presentato un modulo 6-K per comunicare un importante traguardo regolatorio riguardante la sua linea aggiornata di prodotti COVID-19. L'azienda e il partner Pfizer hanno ricevuto una opinione positiva dal Comitato per i Medicinali per Uso Umano (CHMP) dell'Agenzia Europea per i Medicinali, che raccomanda l'autorizzazione alla commercializzazione del loro vaccino COMIRNATY LP.8.1 adattato e monovalente. L'indicazione riguarda l'immunizzazione attiva contro il COVID-19 in individui dai 6 mesi di età in su.

Il parere favorevole del CHMP rappresenta l'ultimo passaggio prima dell'approvazione formale da parte della Commissione Europea, che solitamente avviene entro poche settimane. Se ratificata, la decisione permetterebbe a BioNTech/Pfizer di lanciare il nuovo booster allineato alle varianti in tutta l'UE prima della stagione respiratoria 2025-26, ampliando potenzialmente il mercato indirizzabile anche ai neonati e diversificando le fonti di ricavo.

Nel documento non sono stati comunicati dati finanziari; tuttavia, l'autorizzazione probabilmente sosterrà la continuità delle vendite a breve termine, mentre la domanda per i vaccini di generazione precedente diminuisce. Sono state incluse firme della direzione e un indice degli allegati con riferimento al comunicato stampa congiunto.

BioNTech SE (BNTX) presentó un Formulario 6-K para informar un hito regulatorio clave relacionado con su línea actualizada de productos contra el COVID-19. La compañía y su socio Pfizer recibieron una opinión positiva del Comité de Medicamentos de Uso Humano (CHMP) de la Agencia Europea de Medicamentos que recomienda la autorización de comercialización de su vacuna COMIRNATY LP.8.1 monovalente adaptada. La indicación abarca la inmunización activa contra el COVID-19 en individuos a partir de los 6 meses de edad.

El respaldo del CHMP es el paso final antes de la aprobación formal por parte de la Comisión Europea, que normalmente se produce en pocas semanas. De ser ratificada, la decisión permitiría a BioNTech/Pfizer lanzar el nuevo refuerzo alineado con la cepa en toda la UE antes de la temporada respiratoria 2025-26, ampliando potencialmente el mercado objetivo a bebés y diversificando las fuentes de ingresos.

No se divulgaron cifras financieras en la presentación; sin embargo, la autorización probablemente apoyará la continuidad de las ventas a corto plazo mientras disminuye la demanda de vacunas de generaciones anteriores. Se incluyeron firmas de la dirección y un índice de anexos que hace referencia al comunicado de prensa conjunto.

BioNTech SE (BNTX)는 업데이트된 COVID-19 제품 라인에 대한 중요한 규제 이정표를 보고하기 위해 Form 6-K를 제출했습니다. 회사와 파트너인 Pfizer는 유럽 의약품청(EMA)의 인체용 의약품 위원회(CHMP)로부터 긍정적인 의견을 받아 LP.8.1에 적응된 단가 COMIRNATY LP.8.1 백신의 시판 허가를 권고받았습니다. 이 적응증은 6개월 이상 연령의 개인에 대한 COVID-19 활성 면역을 포함합니다.

CHMP의 승인 의견은 유럽위원회의 공식 승인 전 최종 단계로, 보통 몇 주 내에 이루어집니다. 승인되면 BioNTech/Pfizer는 2025-26 호흡기 계절 전에 EU 전역에 새로운 변종에 맞춘 부스터를 출시할 수 있게 되어, 잠재적으로 영유아 시장을 확대하고 수익원을 다양화할 수 있습니다.

제출 문서에는 재무 수치가 공개되지 않았으나, 승인은 이전 세대 백신 수요가 줄어드는 가운데 단기 매출 지속에 도움이 될 것으로 보입니다. 경영진 서명과 공동 보도자료를 참조하는 전시물 목록도 포함되었습니다.

BioNTech SE (BNTX) a déposé un formulaire 6-K pour signaler une étape réglementaire clé concernant sa gamme mise à jour de produits COVID-19. L'entreprise et son partenaire Pfizer ont reçu un avis positif du Comité des médicaments à usage humain (CHMP) de l'Agence européenne des médicaments recommandant l'autorisation de mise sur le marché de leur vaccin COMIRNATY LP.8.1 monovalent adapté. L'indication couvre l'immunisation active contre la COVID-19 chez les personnes âgées de 6 mois et plus.

L'avis favorable du CHMP est la dernière étape avant l'approbation formelle par la Commission européenne, qui suit généralement dans les semaines qui suivent. Si elle est ratifiée, cette décision permettrait à BioNTech/Pfizer de lancer le nouveau rappel adapté à la souche dans toute l'UE avant la saison respiratoire 2025-26, élargissant potentiellement le marché cible aux nourrissons et diversifiant les sources de revenus.

Aucune donnée financière n'a été divulguée dans le dépôt ; cependant, l'autorisation soutiendrait probablement la continuité des ventes à court terme, alors que la demande pour les vaccins de génération antérieure diminue. Des signatures de la direction et un index des pièces jointes faisant référence au communiqué de presse conjoint ont été inclus.

BioNTech SE (BNTX) hat ein Formular 6-K eingereicht, um einen wichtigen regulatorischen Meilenstein für seine aktualisierte COVID-19-Produktlinie zu melden. Das Unternehmen und sein Partner Pfizer erhielten eine positive Stellungnahme vom Ausschuss für Humanarzneimittel (CHMP) der Europäischen Arzneimittel-Agentur, die die Marktzulassung ihres angepassten, monovalenten COMIRNATY LP.8.1-Impfstoffs empfiehlt. Die Indikation umfasst die aktive Immunisierung gegen COVID-19 bei Personen ab 6 Monaten.

Die CHMP-Befürwortung ist der letzte Schritt vor der formellen Zulassung durch die Europäische Kommission, die in der Regel innerhalb weniger Wochen erfolgt. Wird die Entscheidung bestätigt, könnten BioNTech/Pfizer den neuen, an die Variante angepassten Booster vor der Atemwegssaison 2025-26 in der gesamten EU auf den Markt bringen, was den adressierbaren Markt auf Säuglinge ausweiten und die Einnahmequellen erweitern würde.

Im Bericht wurden keine finanziellen Zahlen offengelegt; die Zulassung dürfte jedoch den kurzfristigen Umsatz aufrechterhalten, während die Nachfrage nach Impfstoffen älterer Generationen zurückgeht. Managementunterschriften und ein Ausstellungsverzeichnis mit Verweis auf die gemeinsame Pressemitteilung wurden beigefügt.

Positive
  • CHMP positive opinion sharply increases likelihood of EU authorization for the LP.8.1-adapted vaccine.
  • Expanded age range (≥6 months) widens target population and future revenue opportunity.
Negative
  • Final EC approval pending; any delay or restrictive labeling could temper commercial gains.

Insights

TL;DR – CHMP thumbs-up de-risks EU launch of BioNTech’s LP.8.1 booster and should bolster FY-25 vaccine revenue.

The positive CHMP opinion materially reduces regulatory risk and signals high probability of European Commission approval. Commercial roll-out to those aged ≥6 months enlarges the eligible population versus prior boosters and counters volume erosion. While exact pricing and uptake remain uncertain, the decision strengthens the company’s COVID-19 franchise and may support consensus revenue estimates. Investors should watch for EC approval timing and subsequent procurement contracts to gauge full impact.

BioNTech SE (BNTX) ha presentato un modulo 6-K per comunicare un importante traguardo regolatorio riguardante la sua linea aggiornata di prodotti COVID-19. L'azienda e il partner Pfizer hanno ricevuto una opinione positiva dal Comitato per i Medicinali per Uso Umano (CHMP) dell'Agenzia Europea per i Medicinali, che raccomanda l'autorizzazione alla commercializzazione del loro vaccino COMIRNATY LP.8.1 adattato e monovalente. L'indicazione riguarda l'immunizzazione attiva contro il COVID-19 in individui dai 6 mesi di età in su.

Il parere favorevole del CHMP rappresenta l'ultimo passaggio prima dell'approvazione formale da parte della Commissione Europea, che solitamente avviene entro poche settimane. Se ratificata, la decisione permetterebbe a BioNTech/Pfizer di lanciare il nuovo booster allineato alle varianti in tutta l'UE prima della stagione respiratoria 2025-26, ampliando potenzialmente il mercato indirizzabile anche ai neonati e diversificando le fonti di ricavo.

Nel documento non sono stati comunicati dati finanziari; tuttavia, l'autorizzazione probabilmente sosterrà la continuità delle vendite a breve termine, mentre la domanda per i vaccini di generazione precedente diminuisce. Sono state incluse firme della direzione e un indice degli allegati con riferimento al comunicato stampa congiunto.

BioNTech SE (BNTX) presentó un Formulario 6-K para informar un hito regulatorio clave relacionado con su línea actualizada de productos contra el COVID-19. La compañía y su socio Pfizer recibieron una opinión positiva del Comité de Medicamentos de Uso Humano (CHMP) de la Agencia Europea de Medicamentos que recomienda la autorización de comercialización de su vacuna COMIRNATY LP.8.1 monovalente adaptada. La indicación abarca la inmunización activa contra el COVID-19 en individuos a partir de los 6 meses de edad.

El respaldo del CHMP es el paso final antes de la aprobación formal por parte de la Comisión Europea, que normalmente se produce en pocas semanas. De ser ratificada, la decisión permitiría a BioNTech/Pfizer lanzar el nuevo refuerzo alineado con la cepa en toda la UE antes de la temporada respiratoria 2025-26, ampliando potencialmente el mercado objetivo a bebés y diversificando las fuentes de ingresos.

No se divulgaron cifras financieras en la presentación; sin embargo, la autorización probablemente apoyará la continuidad de las ventas a corto plazo mientras disminuye la demanda de vacunas de generaciones anteriores. Se incluyeron firmas de la dirección y un índice de anexos que hace referencia al comunicado de prensa conjunto.

BioNTech SE (BNTX)는 업데이트된 COVID-19 제품 라인에 대한 중요한 규제 이정표를 보고하기 위해 Form 6-K를 제출했습니다. 회사와 파트너인 Pfizer는 유럽 의약품청(EMA)의 인체용 의약품 위원회(CHMP)로부터 긍정적인 의견을 받아 LP.8.1에 적응된 단가 COMIRNATY LP.8.1 백신의 시판 허가를 권고받았습니다. 이 적응증은 6개월 이상 연령의 개인에 대한 COVID-19 활성 면역을 포함합니다.

CHMP의 승인 의견은 유럽위원회의 공식 승인 전 최종 단계로, 보통 몇 주 내에 이루어집니다. 승인되면 BioNTech/Pfizer는 2025-26 호흡기 계절 전에 EU 전역에 새로운 변종에 맞춘 부스터를 출시할 수 있게 되어, 잠재적으로 영유아 시장을 확대하고 수익원을 다양화할 수 있습니다.

제출 문서에는 재무 수치가 공개되지 않았으나, 승인은 이전 세대 백신 수요가 줄어드는 가운데 단기 매출 지속에 도움이 될 것으로 보입니다. 경영진 서명과 공동 보도자료를 참조하는 전시물 목록도 포함되었습니다.

BioNTech SE (BNTX) a déposé un formulaire 6-K pour signaler une étape réglementaire clé concernant sa gamme mise à jour de produits COVID-19. L'entreprise et son partenaire Pfizer ont reçu un avis positif du Comité des médicaments à usage humain (CHMP) de l'Agence européenne des médicaments recommandant l'autorisation de mise sur le marché de leur vaccin COMIRNATY LP.8.1 monovalent adapté. L'indication couvre l'immunisation active contre la COVID-19 chez les personnes âgées de 6 mois et plus.

L'avis favorable du CHMP est la dernière étape avant l'approbation formelle par la Commission européenne, qui suit généralement dans les semaines qui suivent. Si elle est ratifiée, cette décision permettrait à BioNTech/Pfizer de lancer le nouveau rappel adapté à la souche dans toute l'UE avant la saison respiratoire 2025-26, élargissant potentiellement le marché cible aux nourrissons et diversifiant les sources de revenus.

Aucune donnée financière n'a été divulguée dans le dépôt ; cependant, l'autorisation soutiendrait probablement la continuité des ventes à court terme, alors que la demande pour les vaccins de génération antérieure diminue. Des signatures de la direction et un index des pièces jointes faisant référence au communiqué de presse conjoint ont été inclus.

BioNTech SE (BNTX) hat ein Formular 6-K eingereicht, um einen wichtigen regulatorischen Meilenstein für seine aktualisierte COVID-19-Produktlinie zu melden. Das Unternehmen und sein Partner Pfizer erhielten eine positive Stellungnahme vom Ausschuss für Humanarzneimittel (CHMP) der Europäischen Arzneimittel-Agentur, die die Marktzulassung ihres angepassten, monovalenten COMIRNATY LP.8.1-Impfstoffs empfiehlt. Die Indikation umfasst die aktive Immunisierung gegen COVID-19 bei Personen ab 6 Monaten.

Die CHMP-Befürwortung ist der letzte Schritt vor der formellen Zulassung durch die Europäische Kommission, die in der Regel innerhalb weniger Wochen erfolgt. Wird die Entscheidung bestätigt, könnten BioNTech/Pfizer den neuen, an die Variante angepassten Booster vor der Atemwegssaison 2025-26 in der gesamten EU auf den Markt bringen, was den adressierbaren Markt auf Säuglinge ausweiten und die Einnahmequellen erweitern würde.

Im Bericht wurden keine finanziellen Zahlen offengelegt; die Zulassung dürfte jedoch den kurzfristigen Umsatz aufrechterhalten, während die Nachfrage nach Impfstoffen älterer Generationen zurückgeht. Managementunterschriften und ein Ausstellungsverzeichnis mit Verweis auf die gemeinsame Pressemitteilung wurden beigefügt.


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549 
FORM 20-F/A
(Amendment No. 1) 
(Mark One) 
¨REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934
OR 
xANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended December 31 2024
OR
¨TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
OR
¨SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of event requiring this shell company report _________
For the transition period from _________ to _________
Commission file number 001-38303
WPP plc
(Exact Name of Registrant as specified in its charter) 
Jersey
(Jurisdiction of incorporation or organization) 
Sea Containers, 18 Upper Ground
London, United Kingdom, SE1 9GL
(Address of principal executive offices) 
Andrea Harris
Group Chief Counsel
Sea Containers, 18 Upper Ground, London, United Kingdom, SE1 9GL
Telephone: +44(0) 20 7282 4600
E-mail: andrea.harris@wpp.com
(Name, Telephone, E-mail and/or Facsimile number and Address of Company Contact Person) 
Securities registered or to be registered pursuant to Section 12(b) of the Act. 
Title of each classTrading Symbol (s)Name of each exchange on which registered
Ordinary Shares of 10p each

WPPLondon Stock Exchange
American Depositary Shares, each
representing five Ordinary Shares (ADSs)
WPPNew York Stock Exchange
Securities registered or to be registered pursuant to Section 12(g) of the Act. 
Not applicable
___________________________________________
(Title of Class) 
Not applicable
____________________________________________
(Title of Class)
Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act. 
None
____________________________________________
(Title of Class) 
Indicate the number of outstanding shares of each of the issuer’s classes of capital or common stock as of the close of the period covered by the annual report. 
At December 31, 2024, the number of outstanding ordinary shares was 1,078,802,358 which included at such date 98,433,160 ordinary shares represented by 19,686,632 ADSs. 
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. 
YesxNo¨
If this report is an annual or transition report, indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. 
Yes¨Nox
Note – Checking the box above will not relieve any registrant required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 from their obligations under those Sections. 
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. 
YesxNo¨
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). 
YesxNo¨
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer, or an emerging growth company. See definition of “large accelerated filer,” “accelerated filer,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large Accelerated Filer
xAccelerated Filer¨
Non-accelerated FileroEmerging Growth Company¨
If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 
¨
The term “new or revised financial accounting standard” refers to any update issued by the Financial Accounting Standards Board to its Accounting Standards Codification after April 5, 2012. 
Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.
x
If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.
x
Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b).
¨
Indicate by check mark which basis of accounting the registrant has used to prepare the financial statements included in this filing:
U.S. GAAP ¨
 International Financial Reporting Standards as issued 
by the International Accounting Standards Board x
Other ¨



If “Other” has been checked in response to the previous question, indicate by check mark which financial statement item the registrant has elected to follow. 
Item 17¨Item 18¨
If this is an annual report, indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). 
YesoNox



Explanatory Note

WPP plc (the “Company”) is filing this Amendment No. 1 (this “Amendment No. 1”) to its annual report on Form 20-F for the fiscal year ended December 31, 2024, as originally filed with the U.S. Securities and Exchange Commission (the “SEC”) on March 28, 2025 (the “Original Filing”), solely for the purpose of correcting typographical errors in Exhibit 8.1 of Item 19 regarding the Company’s subsidiaries.

In addition, the Company is including in this Amendment No. 1 currently dated certifications from its Chief Executive Officer and Chief Financial Officer as required by Rule 12b-15 under the Securities Exchange Act of 1934, as amended, which are attached hereto as Exhibits 12.3 and 12.4, respectively.

Except as described above, no other changes have been made to the Original Filing. This Amendment No. 1 speaks as of the filing date of the Original Filing, or March 28, 2025. Other than as expressly set forth above, this Amendment No. 1 does not, and does not purport to, amend, update or restate the information in any other item of the Original Filing, or reflect any event that has occurred after the filing of the Original Filing. Accordingly, this Amendment No. 1 should be read in conjunction with the Original Filing and the Company’s filings with the SEC subsequent to the filing of the Original Filing.































1


ITEM 19. EXHIBITS
Exhibit No.Exhibit Title
1.1
Memorandum and Articles of Association of WPP plc. (incorporated herein by reference to Exhibit 1.1 of the Registrant's Annual Report on Form 20-F for the year ended 31 December 2021).
2.1
Deposit Agreement dated as of 2  January 2013 among the Registrant, Citibank, N.A. as Depositary, and all holders and beneficial owners from time to time of American Depositary Receipts issued thereunder (incorporated herein by reference to Exhibit 99(A)(I) to the Registrant’s Registration Statement on Form F-6EF filed on 31 December 2012).
2.2
Restricted ADS Letter Agreement dated as of 2 January 2013 between the Registrant and Citibank, N.A., as Depositary (incorporated herein by reference to Exhibit 99(A)(II) to the Registrant’s Registration Statement on Form F-6EF filed on 31 December 2012).
2.3
Agreement of Registrant to file, if requested by the Securities and Exchange Commission, instruments relating to U.S.$500,000,000 3.625% Guaranteed Senior Notes due September 2022 and $300,000,000 5.125% Guaranteed Senior Notes due 2042 (incorporated herein by reference to Exhibit 2.15 of the Registrant’s Annual Report on Form 20-F filed for the year ended 31 December 2012).
2.4
Agreement of Registrant to file, if requested by the Securities and Exchange Commission, instruments relating to U.S.$500,000,000 5.625% Guaranteed Senior Notes due November 2043 (incorporated herein by reference to Exhibit 2.14 of the Registrant’s Annual Report on Form 20-F filed for the year ended 31 December 2013).
2.5
Agreement of Registrant to file, if requested by the Securities and Exchange Commission, instruments relating to €750,000,000 of 2.250% of Senior Notes Due 2026 (incorporated herein by reference to Exhibit 2.14 of the Registrant’s Annual Report on Form 20-F for the year ended 31 December 2014).
2.6
Agreement of Registrant to file, if requested by the Securities and Exchange Commission, instruments relating to €600 million of 1.625% Notes due March 2030 (incorporated herein by reference to Exhibit 2.15 of the Registrant’s Annual Report on Form 20-F for the year ended 31 December 2014).
2.7
Agreement of Registrant to file, if requested by the Securities and Exchange Commission, instruments relating to £400 million (of which £380 million is currently outstanding) 2.875% Notes due September 2046 (incorporated herein by reference to Exhibit 2.14 of the Registrant’s Annual Report on Form 20-F for the year ended 31 December 2016).
2.8
Agreement of Registrant to file, if requested by the Securities and Exchange Commission, instruments relating to €500  million of 1.375% guaranteed senior bonds due March 2025 (incorporated herein by reference to Exhibit 2.15 of the Registrant’s Annual Report on Form 20-F for the year ended 31 December 2017).
2.9
Description of WPP plc Share Capital and American Depositary Shares (incorporated herein by reference to Exhibit 2.11 of the Registrant's Annual Report on Form 20-F for the year ended 31 December 2021).
2.10
Agreement of Registrant to file, if requested by the Securities and Exchange Commission, instruments relating to €750 million of 2.375% guaranteed senior bonds due May 2027 (incorporated herein by reference to Exhibit 2.15 of the Registrant's Annual Report on Form 20-F for the year ended 31 December 2020).
2.11
Agreement of Registrant to file, if requested by the Securities and Exchange Commission, instruments relating to £250 million of 3.75% guaranteed senior bonds due May 2032 (incorporated herein by reference to Exhibit 2.16 of the Registrant's Annual Report on Form 20-F for the year ended 31 December 2020).
2.12
Agreement of Registrant to file, if requested by the Securities and Exchange Commission, instruments relating to EUR 750 million (of which EUR 550 million is currently outstanding) 4.125% guaranteed senior bonds due 30 May 2028.*
2.13
Agreement of Registrant to file, if requested by the Securities and Exchange Commission, instruments relating to EUR 600 million (of which EUR 351 million is currently outstanding) 3.625% guaranteed senior bonds due 12 September 2029.*
2.14
Agreement of Registrant to file, if requested by the Securities and Exchange Commission, instruments relating to EUR 650 million (of which EUR 500 million is currently outstanding) 4.00% guaranteed senior bonds due 12 September 2033.*
2


Exhibit No.Exhibit Title
2.15
U.S. $2,500,000,000 Revolving Credit Facility Agreement dated 20 February 2024, maturing 20 February 2030; made among WPP CP LLC, WPP Finance Co. Limited and WPP CP Finance plc, as Borrowers, and the Guarantors, Facility Agent, Swingline Agent, Lead Arrangers, Bookrunners and Lenders referred to therein
4.1
J. Walter Thompson Company, Inc. Retained Benefit Supplemental Employee Retirement Plan (incorporated herein by reference to Exhibit 4.9 to the Registrant’s Annual Report on Form 20-F for the year ended 31 December 2000).
4.2
Young  & Rubicam Inc. Deferred Compensation Plan (incorporated herein by reference to Exhibit 10.26 to Young & Rubicam’s Registration Statement on Form S-1 (File  No. 333-46929)).
4.3
Amendment No. 2 to Young  & Rubicam Inc. Deferred Compensation Plan effective as of 1 January 1999 (incorporated herein by reference to Exhibit 10.27 to Young  & Rubicam’s Annual Report on Form 10-K for the year ended 31 December 1998).
4.4
Young  & Rubicam Inc. Executive Income Deferral Program (incorporated herein by reference to Exhibit 4.19 to the Registrant’s Annual Report on Form 20-F for the year ended 31 December 2000).
4.5
Ogilvy  & Mather ERISA Excess Plan Summary Plan Description (incorporated herein by reference to Exhibit 4.12 of the Registrant’s Annual Report on Form 20-F for the year ended 31  December 2008).
4.6
Ogilvy  & Mather Executive Savings Plan Summary Plan Description, in connection with a 25% matching contribution (incorporated herein by reference to Exhibit 4.13 of the Registrant’s Annual Report on Form 20-F for the year ended 31 December 2008).
4.7
Ogilvy  & Mather Executive Savings Plan Summary Plan Description, in connection with a 50% matching contribution (incorporated herein by reference to Exhibit 4.14 of the Registrant’s Annual Report on Form 20-F for the year ended 31 December 2008).
4.8
Ogilvy  & Mather Deferred Compensation Plan Summary Plan Description (incorporated herein by reference to Exhibit 4.15 of the Registrant’s Annual Report on Form 20-F for the year ended 31  December 2008).
4.9
WPP plc Annual Bonus Deferral Programme, as amended through 12 November 2012 (incorporated herein by reference to Exhibit 4.12 of the Registrant’s Annual Report on Form 20-F filed for the year ended 31 December 2012).
4.10
GroupM Executive Savings Plan Summary Plan Description (incorporated herein by reference to Exhibit 4.24 of the Registrant’s Annual Report on Form 20-F for the year ended 31 December 2008).
4.11
Grey Advertising Inc. Senior Executive Officer Post-Employment Compensation Plan (incorporated herein by reference to Exhibit 4.40 of the Registrant’s Annual Report on Form 20-F for the year ended 31 December 2008).
4.12
Amendment No. 1 to the Grey Advertising Inc. Senior Executive Officer Post-Employment Compensation Plan, effective as of January 1, 2009 (incorporated herein by reference to Exhibit 4.41 of the Registrant’s Annual Report on Form 20-F for the year ended 31 December 2008).
4.13
Amendment No. 1 to the J. Walter Thompson Retained Benefit Supplemental Employee Retirement Plan, effective as of January 1, 2009 (incorporated herein by reference to Exhibit 4.42 of the Registrant’s Annual Report on Form 20-F for the year ended 31 December 2008).
4.14
WPP plc Executive Performance Share Plan (incorporated herein by reference to Exhibit 4.33 of the Registrant’s Annual Report on Form 20-F filed for the year ended 31 December 2013).
4.15WPP Share Option Plan 2015, amended 5 December 2019.*
4.16
Service Agreement, dated 3  September 2018, between WPP 2005 Limited and Mark Read (incorporated herein by reference to Exhibit 4.26 of the Registrant’s Annual Report on Form 20-F filed for the year ended 31 December 2018).
4.17The WPP plc Stock Plan 2018, amended 9 March 2023.*
4.18
Sale and Purchase Agreement, dated 12  July 2019, as amended, between the Registrant, Summer (BC) Topco S.a r.l., and Summer (BC) UK Bidco Limited (incorporated herein by reference to Exhibit 4.29 to the Registrant’s Annual Report on Form 20-F for the year ended 31 December 2019, as filed with SEC on 30 April 2020).
3


Exhibit No.Exhibit Title
4.19
Securityholders’ Agreement, dated 5 December 2019, between Summer (BC) US JVCO S.C.Sp., Summer (BC) US JVCo GP S.a r.l., Summer (BC) JVCO S.a r.l., York Merger Square 2009 LLC, WPP Diamond Head LLC, WPP 2005 Limited, Summer (BC) Topco S.a r.l., and Summer (BC) US Blockerco Corp (incorporated herein by reference to Exhibit 4.30 to the Registrant’s Annual Report on Form 20-F for the year ended 31 December 2019, as filed with SEC on 30 April 2020).
4.20
WPP plc Executive Performance Share Plan (incorporated herein by reference to Exhibit 4.26 to the Registrant’s Annual Report on Form 20-F for the year ended 31 December 2022, as filed with SEC on 31 March 2023).
8.1
List of Subsidiaries 2024 - Amended**
11WPP plc Dealing Code*
12.1Certification of Chief Executive Officer.*
12.2Certification of Chief Financial Officer.*
12.3
Certification of Chief Executive Officer - Amended**
12.4
Certification of Chief Financial Officer - Amended**
13.1Certification of Chief Executive Officer under 18 U.S.C. Section 1350.*
13.2Certification of Chief Financial Officer under 18 U.S.C. Section 1350.*
14.1Consent of Independent Registered Public Accounting Firm - PwC (for WPP plc and subsidiaries).*
14.2Consent of Independent Registered Public Accounting Firm - Deloitte (for WPP plc and subsidiaries).*
17.1List of subsidiary guarantors and issuers of guaranteed securities.*
97The WPP Compensation Recovery Policy, dated 1 December 2023.*
101.INSInline XBRL Instance Document*
101.SCHInline XBRL Taxonomy Extension Schema Linkbase Document*
101.CALInline XBRL Taxonomy Extension Calculation Linkbase Document*
101.DEFInline XBRL Taxonomy Extension Definition Linkbase Document*
101.LABInline XBRL Taxonomy Extension Label Linkbase Document*
101.PREInline XBRL Taxonomy Extension Presentation Linkbase Document*
104Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)*
 _________________
*    Incorporated by reference with the corresponding exhibit number from the 20-F filed March 28, 2025.
**    Filed herewith.








4


Signatures
The Registrant hereby certifies that it meets all of the requirements for filing on Form 20-F/A and that it has duly caused and authorized the undersigned to sign this Amendment No. 1 to the annual report on its behalf.
WPP plc
By:/s/ Joanne Wilson
Joanne Wilson
Chief Financial Officer
25 July 2025

5

FAQ

What did BioNTech (BNTX) announce in its July 25, 2025 Form 6-K?

A positive CHMP opinion recommending EU marketing authorization for the LP.8.1-adapted COMIRNATY vaccine.

Which age groups are covered by the new LP.8.1 vaccine recommendation?

Individuals 6 months of age and older are included in the indication.

Is the vaccine fully approved in the European Union?

Not yet; the CHMP opinion must be ratified by the European Commission before sales can begin.

Why is the CHMP opinion significant for investors?

It substantially de-risks regulatory approval and may sustain BioNTech’s COVID-19 revenue trajectory.

Does the filing contain financial results or guidance?

No. The 6-K focuses solely on the regulatory update without disclosing financial figures.
Wpp Plc

NYSE:WPP

WPP Rankings

WPP Latest News

WPP Latest SEC Filings

WPP Stock Data

6.34B
215.76M
10.48%
0.18%
Advertising Agencies
Communication Services
Link
United Kingdom
London